ARTICLE | Translation in Brief

Preempting Lassa

How Kineta is aiming to stay one step ahead of Lassa fever

June 30, 2016 7:00 AM UTC

With the announcement of positive preclinical results for its Lassa fever compound in April and an award of up to £5 million ($6.7 million) from the Wellcome Trust in May, Kineta Inc. is aiming to get ahead of what could be the next major viral hemorrhagic fever outbreak in Africa.

CEO Shawn Iadonato told BioCentury that both the World Health Organization (WHO) and NIH's National Institute of Allergy and Infectious Diseases (NIAID) have added Lassa to their lists of viruses most likely to become emerging threats in the future, yet there are no approved drugs for the infection...